Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Open Access
- 18 January 2024
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology, 2021
- FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemiaBritish Journal of Haematology, 2019
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantationHaematologica, 2016
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- How I treat refractory and early relapsed acute myeloid leukemiaBlood, 2015
- Management of Refractory Acute Myeloid Leukemia: Re-induction Therapy or Straight to Transplantation?Current Hematologic Malignancy Reports, 2011
- Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.1996
- Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactionsBlood, 1996